File:Degarelix Benefits to Reduce the Risk of Cardiovascular Events in Prostate Cancer Treatment.docx
From OpenWetWare
Jump to navigationJump to search
Degarelix_Benefits_to_Reduce_the_Risk_of_Cardiovascular_Events_in_Prostate_Cancer_Treatment.docx (file size: 13 KB, MIME type: application/zip)
Warning: This file type may contain malicious code. By executing it, your system may be compromised.
Degarelix (INN) or degarelix acetate (USAN) (trade name Firmagon) has an immediate onset of action, binding to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocking their interaction with GnRH. Reference can be found at http://www.creative-peptides.com/product/degarelix-item-10-101-132-37.html.
File history
Click on a date/time to view the file as it appeared at that time.
| Date/Time | Dimensions | User | Comment | |
|---|---|---|---|---|
| current | 01:37, 16 June 2016 | (13 KB) | Chloe Mica (talk | contribs) | Degarelix (INN) or degarelix acetate (USAN) (trade name Firmagon) has an immediate onset of action, binding to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocking their interaction with GnRH. Reference can be found at http |
You cannot overwrite this file.
File usage
There are no pages that use this file.
